Sentences with phrase «immunotherapy combinations with»

Not exact matches

U.S. drug giant Merck is paying $ 300 million in a deal possibly worth more than $ 5 billion to partner Eisai in an effort to boost its star cancer immunotherapy treatment Keytruda, which could match up well in a combination with Eisai's Lenvima.

And using lower levels of Yervoy in combination with Opdivo actually prompted more tumor shrinkage, underscoring the fact that dosing is a critical and unpredictable factor for immunotherapies.

In addition to formulating diagnostic strategies for cancer immunotherapy agents, her team is focused on developing a deep understanding of tumor immune biology as well as mechanisms associated with immune response and immune escape in cancer patients, with the intent of generating rational strategies for the creation of combination therapies.

Roche has four biologic cancer immunotherapy molecules in clinical trials that could work in powerful combinations with each other or with current drugs, says William Pao, global head of oncology discovery in Basel.

They studied the effects of this treatment in combination with ipilimumab, a U.S. Food and Drug Administration - approved immunotherapy.

«Immunotherapy combination promising for untreated patients with advanced melanoma.»

«Our study reveals a previously unknown mechanism that we might be able to block to make tumors «visible» again to attacking immune cells, perhaps in combination with other immunotherapies,» says Miller, also an associate professor in the Department of Cell Biology.

They suggest allocating greater resources to research focused on immune checkpoint therapies and targeted / immunotherapy combination therapies with «curative potential.»

To investigate why checkpoint inhibitors so often stop working, Velculescu; Valsamo Anagnostou, M.D., Ph.D., instructor of oncology at the Johns Hopkins University School of Medicine; Kellie N. Smith, Ph.D., a cancer immunology research associate at the Johns Hopkins University School of Medicine; and their colleagues at the Bloomberg ~ Kimmel Institute for Cancer Immunotherapy studied tumors of four patients with non-small cell lung cancer and one patient with head and neck cancer who developed resistance to two different checkpoint inhibitors: a drug called nivolumab that uses an antibody called anti-PD-1, or nivolumab used alone or in combination with a second drug called ipilimumab, which uses an antibody called anti-CTLA4.

Cancer immunotherapy is mainly applied in combination with chemotherapy and radiotherapy.

The ultimate goal is to precisely understand the mechanisms of checkpoint blockade effectiveness and bring next generation, sustainable immunotherapies to even more patients, perhaps using by using epigenetic drugs in combination with checkpoint blockade to allow epigenetic reprogramming of exhausted T cells into durable and functional memory T cells.

Combination therapy with two immunotherapy drugs produces an unprecedented doubling of response rates from 20 percent to 40 percent, a new study shows.

Combination immunotherapy with nivolumab and ipilimumab as tested in the kidney cancer study described here is already FDA - approved for treatment of melanoma, and is being tested for other cancers.

«The next step is to perform preclinical studies with specific inhibitors of HDAC11 alone and in tandem with other existing immunotherapies, such as anti-PD1 / anti-PDL1 antibodies, in order to find the most potent combination.

If their effectiveness increases in combination with immunotherapies, as early evidence indicates, that potential may be greater than is even now apparent.

The researchers say the results warrant further development of neoantigen vaccines, both alone and in combination with other immunotherapy weapons such as checkpoint inhibitors.

At Thursday's Winship symposium on cancer immunotherapy, Rafi said the name of the game is now combinations, with an especially good one being PD - 1 inhibitors plus IL2.

To meet this end, CCIR members take advantage of resources offered by MD Anderson, including the CCSG Shared Resources, Immune Monitoring Core Laboratory and GMP Cell Facility, allowing them to follow the «bench - to - beside» approach to develop and improve cancer immunotherapy in the form of cellular therapy, a vaccine or targeting antibody, either alone or in combination with conventional therapies or newly developed therapies.

A Phase 1b / 2 Open - Label Study to Evaluate Safety, Clinical Activity, Pharmacokinetics and Pharmacodynamics of Avelumab (MSB0010718C) in Combination with Other Cancer Immunotherapies in Patients with Advanced Malignancies

-- Checkmate Pharmaceuticals of Cambridge, MA, has nudged its way into the combination immunotherapy game with promising early data presented Monday.

Early this week, the U.S. Food and Drug Administration (FDA) approved a combination immunotherapy regimen for treating certain patients newly diagnosed with advanced renal cell carcinoma, the most common form...

She has identified novel immune - modulating activities associated with targeted cancer drugs in preclinical models, and developed synergistic immunotherapy combinations.

Hepatocyte growth factor (HGF)(or scatter factor (SF) pathways - Met inhibitors could be used in combination with other treatment modalities such as; radiotherapy and / or immunotherapy in treatment of cutaneous melanoma.

One strategic avenue that Sharma and her colleagues are exploring to enhance checkpoint immunotherapy's effectiveness in more tumor types involves targeting other immune - related pathways in combination with existing immunotherapies.

Upcoming interventional trials will examine immunotherapy in combination with other novel agents in an effort to improve both short - and long - term outcomes for patients.

Sharma spoke about one example of this approach: a recently launched CRI Clinical Accelerator trial testing a CD40 - based immunotherapy in combination with checkpoint immunotherapy and chemotherapy for patients with pancreatic cancer.

Additional trials utilizing this vaccine are ongoing in glioblastoma, while a vaccine and checkpoint immunotherapy combination trial is being planned for patients with bladder cancer.

Current clinical trials include combination of intrahepatic embolization and a radiosensitizer in patients with uveal melanoma and liver - only metastases, a phase I trial that evaluates a combination therapy of BCG with ipilimumab in Stage III / IV melanoma, and several landmark international trials including a phase II trial that evaluates combination immunotherapy with nivolumab & ipilimumab.

With investigators and clinicians from the Wistar Institute, University of Pennsylvania, Merck Pharmaceuticals, and Philadelphia FIGHT, Objective 2 (IRF2) focuses on stimulating the immune system with which we are all born (innate immunity), through a combination immunotherapy approach using highly - potent antibodies against HIV, together with pegylated interferon alphaWith investigators and clinicians from the Wistar Institute, University of Pennsylvania, Merck Pharmaceuticals, and Philadelphia FIGHT, Objective 2 (IRF2) focuses on stimulating the immune system with which we are all born (innate immunity), through a combination immunotherapy approach using highly - potent antibodies against HIV, together with pegylated interferon alphawith which we are all born (innate immunity), through a combination immunotherapy approach using highly - potent antibodies against HIV, together with pegylated interferon alphawith pegylated interferon alpha 2b.

Some of the above immunotherapies are used in combination with chemotherapy, which causes long - lasting damage in these growing children.

Patients with these pathogenic autoantibodies may respond well to a combination of antiepileptic drugs and immunotherapy.

The study suggests that combination immunotherapy with both CD19 and CD22 may produce longer - lasting remissions.

The team will identify genetic and epigenetic features in CAR T cells and / or cancer cells that will help predict which patients will respond to the immunotherapy, with an eventual goal of initiating clinical trials that employ a combination of approaches to therapy.

Immunotherapy can be used for many types of cancer, either alone or in combination with other treatments.

A combination of complementary immunotherapy drugs brentuximab vedotin (Adcetris ®) and nivolumab (Opdivo ®) destroyed most cancer cells in 64 percent of patients with recurrent Hodgkin lymphoma, according to the results of an early - phase clinical trial led by Catherine M. Diefenbach, MD, assistant professor of medicine and director of the Clinical Lymphoma Program.

Combination of Turnstone's oncolytic viral immunotherapy with checkpoint inhibitors showed promising results in preclinical testing

In particular, Dr. Azad's laboratory and clinical trials explore epigenetic therapy in combination with chemotherapy and immunotherapy to improve survival for patients, as well as molecularly targeted drugs.

In particular, the goals are to investigate patient epigenetic variation that influences the response to immunotherapy and to use epigenetic therapeutics alone or in combination with immunotherapy to inhibit tumor progression as well as to overcome resistance to immunotherapy.

In the combination study, patients receive either CMB305 combined with Genentech's cancer immunotherapy, TECENTRIQ ® (atezolizumab, anti-PD-L1), or atezolizumab alone, pursuant to a collaboration with Genentech.

Phase 1b study of a novel immunotherapy combination therapy of intralesional Coxsackievirus A21 and systemic ipilimumab in patients with advanced melanoma.

Details of a first - in - human case report showed that a patient with melanoma was able to achieve a durable complete response with the combination of two types of immunotherapy.

Researchers are investigating nanoparticles for delivery of immunostimulatory or immunomodulatory molecules in combination with chemo - or radiotherapy or as adjuvants to other immunotherapies.

Now, we're conducting clinical trials to test these targeted therapies in combination with immunotherapy to treat KRAS - driven NSCLC.

Preliminary analyses of the results of the first combination trials, which show higher response rates than with either agent alone, offer some optimism that these locoregional therapies will find application — as treatment for patients who can not tolerate systemic immunotherapies, to alleviate locoregional morbidity, and perhaps even to «prime» the immune system.

The Delaney Collaboratory to Cure HIV - 1 Infection by Combination Immunotherapy (BEAT - HIV Collaboratory) is a consortium of more than 30 top HIV researchers from leading academic research institutions working with government, nonprofit organizations, and industry partners to test combinations of several novel immunotherapies under new preclinical research and clinical trials.

«Immune checkpoint inhibitors, including PD - 1 and PD - L1 inhibitors, have provided meaningful clinical benefits for patients with cancer; however, novel immunotherapy combination treatments are needed to improve efficacy with limited additive toxicity,» said Aung Naing, MD, FACP, associate professor, Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston.

The children received omalizumab or a placebo for eight weeks before starting immunotherapy and for eight weeks during combination treatment with immunotherapy for two to five trigger foods.

However, we have found that dogs with low - grade glioma respond well to the combination of surgery and immunotherapy, and we are prolonging the disease free interval for dogs with high - grade glioma while providing an excellent quality of life.

As an immunotherapy, it can be given in combination with pain medications or used in dogs that do not tolerate pain medications.

Typically, cancers may be treated with combinations of surgery, chemotherapy, radiation therapy, and sometimes immunotherapy.